Jornal Internacional de Desenvolvimento e Pesquisa de Drogas

• Página inicial do diário
• Arquivo
Autores
• Diretrizes para Autores
• Enviar manuscrito
Em detalhe
• Objetivo e escopo
• Ética de publicação
• Processo de revisão por pares
• direito autoral
• Contate-nos

Abstrato

Biphase Drug Delivery Systems Carrying Nanocomposite Particles

Thomas Ende

Magnetite nanoparticles and poly (D,L-lactide-co-glycolide) (PLGA) were combined to create drug-carrying magnetic nanocomposite spheres for magnetic targeted drug delivery. Through the chemical coprecipitation of ferric and ferrous chloride salts in the presence of a potent basic solution, magnetic nanoparticles of magnetite (average size: 13 nm) were created (ammonium hydroxide). For the synthesis of nanocomposite spheres, an oil-in-oil emulsion/solvent evaporation process was used, with agitation lasting 1.5 to 2 hours at 7000 rpm. Specifically, acetonitrile (oily phase I) was used to dissolve the PLGA and drug, which was subsequently mixed with magnetic nanoparticles. Next, Span 80- and viscous paraffin oil-containing droplets were added in a dropwise fashion (oily phase II). Using dynamic laser light scattering (DLLS), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and a superconducting quantum interference device, the nanocomposite spheres with various amounts (0%, 10%, 20%, and 25%) of magnetite were assessed in terms of particle size, morphology, and magnetic properties (SQUID). According to the findings, nanocomposite spheres with diameters ranging from 200 nm to 1.1 m are superparamagnetic over blocking temperatures close to 40 K and reach magnetization saturation beyond 5,000 Oe at ambient temperature.

Successful attempts have been made to synthesise and analyse pseudopolyrotaxanes made composed of polyethylene glycol axes with end thymine groups and -cyclodextrin rings. The principal drug delivery system, PPR-Fl, was created by conjugating fluorescein, a model drug, to the hydroxyl functional groups of the cyclodextrin rings of PPR via ester bonds. By forming hydrogen bonds with a complementary molecule like polycitric acid, citric acid, or adenine, the PPR-Fl was finally sealed off. This research sought to modulate the noncovalent interactions between stoppers and thymine end groups in order to regulate the release of fluorescein-cyclodextrin conjugates from PPR-Fl, which served as secondary drug delivery systems. It was discovered that pH had the ability to regulate the rate of Fl-CD release from PPR-Fl.